IL-17 and Its Receptor System: a New Target for Psoriatic Arthritis

Raychaudhuri, Smriti K.; Raychaudhuri, S. P.

doi:10.1007/s40674-015-0019-2

Cited by 2 publications

(1 citation statement)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…New molecules (Bimekizumab) are on the pipeline for clinical practice [ 2 ]. Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody which selectively binds to IL-17 and prevents interaction with its receptor [ 3 ]. Immune-mediated inflammatory diseases, like psoriasis and inflammatory bowel disease (IBD), share the same pathogenic mechanisms involving IL-23, IL-17, Th17 and tumor necrosis factor (TNF), leading to the need for the same pharmacological treatments [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

New onset severe ulcerative colitis following Ixekizumab therapy

Morosanu¹,

Mihai

Rezus

et al. 2022

Arch Clin Cases

View full text Add to dashboard Cite

Ixekizumab is one of the three biologic agents including Secukinumab and Brodalumab that targets the Interleukin-17 (IL-17) pathway to reduce inflammation in psoriasis and ankylosing spondylitis. In this report we present the case of 42-year-old woman, who was diagnosed with psoriasis and psoriatic arthritis. One week after first administration of Ixekizumab, she developed diffuse abdominal pain, bloody diarrhea (7-8 stools/day) and fever. Following imaging (colonoscopy, computed tomography) and laboratory investigations, she was diagnosed with acute severe ulcerative colitis complicated with toxic megacolon. The medical treatment (first corticotherapy, then infliximab) has failed and the patient needed emergency colectomy. Based on the immunological mechanisms and the observation from other studies, Ixekizumab should be considered an etiology for new-onset inflammatory bowel disease.

show abstract

Section: Introductionmentioning

confidence: 99%